ArticleDrug design, development and therapy2026
Real-World Outcomes of Aflibercept 2 mg Using a Treat-and-Extend Protocol for Neovascular Age-Related Macular Degeneration: A 24-Month Retrospective Study in a Chinese Population.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the long-term efficacy of aflibercept using a treat-and-extend (T&E) protocol in Chinese patients with neovascular age-related macular degeneration (nAMD) and to explore baseline imaging predictors of treatment response. Methods: This retrospective, real-world study included patients with treatment-naïve nAMD who received intravitreal aflibercept (2.0 mg) under a T&E regimen for 24 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and OCT-derived structural features were assessed. Patients were stratified into effective and non-effective groups based on visual outcomes at 24 months. Results: A total of 37 eyes were included. Compared with baseline (0.71±0.48 logMAR), BCVA improved significantly at 3 months (0.58±0.50, p=0.029), 6 months (0.51±0.32, p<0.01), and remained improved at 24 months (0.57±0.44, p=0.002). Mean ΔBCVA at 24 months was -0.15±0.27 logMAR. CMT decreased from 409.89±219.24 μm at baseline to 277.43±113.92 μm at 3 months (p<0.001), with sustained reductions throughout follow-up (ΔCMT -145.71±239.50 μm at 24 months). Subretinal fluid (SRF), intraretinal fluid (IRF), and pigment epithelial detachment height (PEDH), resolved significantly during follow-up (all p ≤ 0.05), whereas hyperreflective dots (HRD), subretinal hyperreflective exudation (SHE), fibrosis, and macular atrophy (MA) tended to increase progressively. In subgroup analysis, the effective group showed higher baseline CMT (473 vs 293 μm, p=0.015), more frequent SRF (70.8% vs 30.8%, p=0.019), and more HRD (79.2% vs 46.2%, p=0.041). Multivariate logistic regression confirmed higher baseline CMT (OR=1.01, p=0.030) and SRF presence (OR=5.40, p=0.028) as independent predictors of visual response. Conclusion: Intravitreal aflibercept administered under a T&E regimen provides sustained visual and anatomical benefits in Chinese patients with nAMD. Baseline OCT features, particularly CMT and SRF, are valuable predictors of treatment efficacy, supporting their role in individualized therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.